论文部分内容阅读
大多数转移性乳腺癌患者对各种常规剂量的联合化疗敏感 ,但只有不到 5 %的患者在发现转移后可生存 1 0年。早期的临床 期试验报道 ,对化疗敏感的转移性乳腺癌患者进行大剂量化疗 (HDC)加自体造血干细胞移植 (AHSCT)可获得满意的结果 ,包括完全缓解 (CR)和部分缓解 (PR)的有效?
Most patients with metastatic breast cancer are sensitive to various combinations of conventional doses of chemotherapy, but less than 5% survive 10 years after they are found to have metastasized. Early clinical trials have reported satisfactory results for high-dose chemotherapy (HDC) plus autologous hematopoietic stem cell transplantation (AHSCT) in patients with chemotherapy-sensitive metastatic breast cancer including complete remission (CR) and partial remission effective?